peanut_allergen_powder_dnfp_medical_necessity_review
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage stance for peanut allergen powder-dnfp (Palforzia) for Medicare Advantage and commercial products, with clinical background, trial evidence summary, billing guidance (unlisted HCPCS J8499), and benefit-direction to refer to contract benefits.
No material clinical or coverage changes were made in this update.
Coverage Summary & Determination
Palforzia (Peanut [Arachis hypogaea] allergen powder-dnfp) is an oral peanut allergen powder used as oral immunotherapy to desensitize patients to peanut. The FDA approved Palforzia on January 31, 2020 for mitigation of allergic reactions, including anaphylaxis, that may occur with accidental peanut exposure in patients with a confirmed peanut allergy; initial dose escalation is approved for ages 4 through 17 years and up‑dosing/maintenance may continue in patients 4 years and older. Despite evidence of increased desensitization in trials, this policy states the product is not covered for Medicare Advantage plans and not medically necessary for commercial products because the evidence is insufficient to determine effects on net health outcomes.
Medicare Advantage Coverage Determination
Coverage decision statement:
Commercial Products Coverage Determination
Coverage decision statement:
Actions for Providers / Billing Impact
Refer to benefit contract
Benefits and coverage can differ by group and contract. Providers should refer to the member's applicable Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for specific coverage determinations before providing or billing for Palforzia.
Use unlisted HCPCS code for claims
There is no specific CPT code for Palforzia. Claims for Palforzia should be filed using the unlisted HCPCS code listed below.
Potential claim denial for non-covered therapy
Palforzia is considered not covered for Medicare Advantage plans and not medically necessary for commercial products under this policy; claims may therefore be denied or not reimbursed per the applicable coverage determination.
Coding Guidance
| J8499 | Prescription drug, oral, non-chemotherapeutic, NOS (unlisted HCPCS suggested for Palforzia) |
Clinical Background and Evidence Summary
Palforzia is a defatted, slightly roasted peanut flour formulated with a characterized peanut allergen profile and administered orally in gradually increasing doses as immunotherapy to desensitize patients. The U.S. Food and Drug Administration approved Palforzia on January 31, 2020 for mitigation of allergic reactions from accidental peanut exposure in patients with a confirmed peanut allergy; initial dose escalation is authorized for ages 4–17 years and maintenance/up‑dosing may be continued in patients 4 years and older. Standard care for peanut allergy remains strict avoidance of peanut-containing foods and prompt treatment of reactions (including epinephrine). Clinical trials (PALISADE, ARTEMIS, RAMSES) demonstrated increased proportions of patients tolerating challenge doses of peanut protein but also showed higher rates of adverse events and uncertainty about long-term net health benefit, leading to insufficient evidence to support coverage.
| Study / Endpoint | Result |
|---|---|
| PALISADE primary endpoint | 67.2% treated vs 4.0% placebo could ingest ≥600 mg peanut protein without dose-limiting symptoms (difference 63.2%, 95% CI 53.0 to 73.3, p<.001) |
| ARTEMIS primary endpoint | 58% treated vs 2% placebo could tolerate 1000 mg peanut protein (p<.0001) |
| Adverse events increased | Higher rates in treated group: serious AEs (2.2% vs 0.8%), systemic allergic reactions (14.2% vs 3.2%), epinephrine use outside challenge (14.0% vs 6.5%), withdrawal due to AEs (11.6% vs 2.4%) |
Definition: Peanut (Arachis hypogaea) allergen powder-dnfp — a defatted, slightly roasted peanut flour with a characterized peanut allergen profile used for oral immunotherapy (Palforzia) administered in gradually increasing oral doses to desensitize patients to peanut.
Revision History
FDA approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) for mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut; initial dose escalation for ages 4–17 and up-dosing/maintenance for patients 4 years and older.
Policy effective date establishing coverage determinations: not covered for Medicare Advantage plans and not medically necessary for commercial products due to insufficient evidence on net health outcomes.
Policy last reviewed; reaffirmed coverage stance noting trial evidence (PALISADE, ARTEMIS, RAMSES) showing increased desensitization but higher adverse events and insufficient long-term net health benefit.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.